The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Endometrial cancer becomes a three-horse race
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
ASCO 2024 – AstraZeneca’s GPC3 secret sauce
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
